An intranasal adjuvanted recombinant influenza vaccine appeared to safely prompt a robust response to a range of H5N1 clades, according to a phase I trial. Immune responses among the three groups that ...

A new vaccine being developed for whooping cough could offer better protection and stop the infection spreading, scientists ...

Despite existing NHS vaccines for babies, children, and pregnant women, a government-funded trial showed the BPZE1 nasal ...

Researchers have developed an intranasal COVID-19 vaccine that enhances the immune system’s response to the virus, providing longer-lasting, greater protection than vaccine injections, even against ...

In June, the CDC recommended hospitals stop using the FluMist Quadrivalent flu vaccine for immunizations leading into the upcoming 2016-2017 flu season. However, new research in mice from Columbia ...

The Food and Drug Administration (FDA) has approved the first nasal spray flu vaccine which can be administered by the patient or a caregiver. FluMist, produced by European pharmaceutical company and ...

In hopes of staying ahead of an evolving SARS-Cov-2 virus, scientists turn to intranasal vaccines to trigger mucosal immunity. Issue: Despite huge scientific gains in developing the original group of ...

Current vaccines have greatly diminished the severity of the COVID-19 pandemic, even though they do not entirely prevent infection and transmission, likely due to insufficient immunity in the upper ...

In a phase I trial, an intranasal adjuvanted recombinant influenza vaccine appeared to result in response to a range of H5N1 clades. The adjuvanted vaccine elicited seroconversion against clade 2 ...